Improvement of health related quality of life in patients with recurrent glioma treated with bevacizumab plus daily temozolomide as the salvage therapy

Publication date: June 2018
Source:Clinical Neurology and Neurosurgery, Volume 169
Author(s): Yong Liu, Fuqiang Feng, Peigang Ji, Bolin Liu, Shunnan Ge, Chen Yang, Miao Lou, Jinghui Liu, Baofu Li, Guodong Gao, Yan Qu, Liang Wang
ObjectivesBevacizumab (BEV) plus daily temozolomide (TMZ) as a salvage therapy have been recommended to recurrent glioma. The objective of this retrospective study was to evaluate the effect of the combined regimen on health related quality of life (HRQL) and treatment response in patients with recurrent glioma.Patients and MethodsTwenty patients with recurrent glioma were treated with BEV (5–10 mg/kg, i.v. every 2 weeks) plus daily TMZ (daily, 50 mg/m²). The treatment response was evaluated via the RANO criteria. HRQL were measured using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire core 30 (QLQ-C30) and Brain Module (QLQ-BN20).ResultsTwenty patients received a total of 85 cycles of BEV with a median number of 4 cycles (range: 2–10). No patients showed complete response (CR) to treatment. Twelve patients had partial response (PR), stable disease (SD) in 5 patients with, and 3 patients showed progressive disease (PD). In the functioning domains of QLQ-C30, physical functioning, cognitive functioning and emotional functioning significantly improved after the second cycle of BEV compared to baseline, with the mean score of 45.0 vs. 64.0 (p = 0.020), 55.8 vs. 71.7 (p = 0.020) and 48.3 vs. 67.5 (p = 0.015), respectively. In the symptom scales, the scores of pain and nausea/vomiting significantly decreased compared to baseline from the mean score of 39.1 to 20.0 (p = 0.020) and 29.2 to 16.7 (p = 0.049), respectively. Score of global health status also increased from 47.5 to 63.3 (p = 0.001). As determined with the QLQ-BN20, motor dysfunction (43.3 vs. 25.0, p = 0.021), weakness of legs (36.7 vs. 18.3, p = 0.049), headache (38.3 vs. 20.0, p = 0.040), and drowsiness (50.0 vs. 30.0, p = 0.026) after the second cycle of BEV also significantly improved compared to baseline.ConclusionBEV plus daily TMZ as a salvage therapy improved HRQL in patients with recurrent glioma.



from #ORL-AlexandrosSfakianakis via ola Kala on Inoreader https://ift.tt/2H5pJEW